BridgeBio Presents Results of Encaleret in P-IIb Study for the Treatment of ADH1 at ENDO 2021

 BridgeBio Presents Results of Encaleret in P-IIb Study for the Treatment of ADH1 at ENDO 2021

BridgeBio Presents Results of Encaleret in P-IIb Study for the Treatment of ADH1 at ENDO 2021

Shots:

  • The ongoing P-IIb POC, open-label study involves assessing Encaleret (starting dose: 30 mg) in 6 patients for the treatment of ADH1
  • The results showed normalization of blood calcium and urine calcium, well-tolerated and consistent mineral responses with no serious AEs, and no AEs of moderate or severe intensity reported after 5 days, at doses up to 180 mg
  • Encaleret could be the 1st approved therapy option indicated specifically for the treatment of ADH1, if the development program is successful

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: PRNewswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post